Why the study?
There is a lack of consensus on the optimal therapy for arterial thrombosis in cancer patients, and best practices for managing an aortic thrombus remain to be reviewed.
Does low molecular weight heparin (LMWH) resolve aortic thrombus in a patient with cancer-associated arterial thrombosis?
Does low molecular weight heparin (LMWH) resolve aortic thrombus in a patient with cancer-associated arterial thrombosis?
LMWH successfully resolved an asymptomatic ascending aortic thrombus in a patient with advanced lung cancer on chemo-immunotherapy, suggesting it as a viable non-invasive management strategy.
Answers are grounded in this paper and cite their sources.
LMWH may resolve cancer-associated aortic thrombus; single case leaves open need for prospective validation before practice change.
Background: Arterial thrombosis is an uncommon complication in cancer patients, often overshadowed by venous thromboembolic events. Its occurrence in patients with solid tumors on active antineoplastic treatment poses a significant clinical challenge. Key clinical question: Given the lack of consensus on the optimal therapy for arterial thrombosis in cancer patients, the best practices for managing an aortic thrombus, and the benefit of low molecular weight heparin (LMWH) must be reviewed. Clinical approach: We present the case of a 70-year-old female with stage IVA lung adenocarcinoma who developed an aortic thrombus during chemo-immunotherapy. The thrombus was successfully treated with LMWH, avoiding further complications, and allowing for the continuation of her cancer therapy. Conclusions: This case highlights the importance of early detection and management of arterial thrombus in cancer patients. LMWH proved effective in resolving the thrombus, underscoring its role in managing such complications.
No takes yet. Share an insight, caveat, or question.
Borregón et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: